GlassScriptPhysician profile
Sania Saeed
NPI 1104425404
$1,101.23
in general payments reported to CMS, 2019-2025
17 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $51.36 · 2022: $625 · 2024: $424.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $407 · Education: $17.63.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $406.86 |
| Education | $17.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $225.72 | 2022 | |
| Abbvie INC. | $140.73 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $123.16 | 2022 | |
| Idorsia Pharmaceuticals US INC | $110.00 | 2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $77.13 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $70.66 | 2024 | Entyvio |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $57.49 | 2024 | Xifaxan, Trulance |
| Pfizer INC. | $53.33 | 2024 | |
| Qol Medical, LLC | $45.35 | 2024 | Sucraid |
| Regeneron Healthcare Solutions, INC. | $38.48 | 2024 | Dupixent |
| Lilly USA, LLC | $31.17 | 2024 | Omvoh |
| Daiichi Sankyo INC. | $27.94 | 2024 | Injectafer |
| Ipsen Biopharmaceuticals, INC | $25.14 | 2024 | Iqirvo |
| Janssen Biotech, INC. | $21.91 | 2024 | Stelara |
| Celgene Corporation | $20.15 | 2024 | Zeposia |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celltrion USA INC. | $17.63 | 2024 | Zymfentra |
| Phathom Pharmaceuticals, INC. | $15.24 | 2024 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sania Saeed listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.